WuXi Biologics

Update in progress

WXXWY (OTC Markets OTCPK)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

WuXi Biologics (Cayman) Inc. is an investment holding company providing end-to-end biologics discovery, development and manufacturing services. It serves customers in China, North America, Europe, Singapore, Japan, Korea and Australia, and operates in two segments: Biologics and XDC. It supports concept-to-IND discovery, CMC and downstream process development via platforms such as WuXiBody and single B cell cloning. It also offers consulting, testing, vaccine CDMO and related services, plus collaboration with BioNTech on monoclonal antibodies and with Sinorda Biomedicine on SND006 bispecific antibody. Founded 2014, based in Wuxi, China.

Company score

Sentiment: 0.65; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.54; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.49; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.36; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.50; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive